Form 4: Tandem Diabetes Care Director Dick Allen Reports Stock Transactions and New RSU Grant

Tandem Diabetes Care Inc. Director Dick Allen reported the acquisition of common stock through RSU vesting and a new grant of restricted stock units, increasing his direct and indirect holdings.

Summary

• Director Dick Allen of Tandem Diabetes Care Inc. reported transactions involving company stock on May 21 and May 22, 2025.
• On May 22, 2025, Allen acquired 4,387 shares of common stock at a price of $20.64 per share, resulting from the vesting of previously awarded Restricted Stock Units (RSUs).
• Concurrently, 4,387 Restricted Stock Units were disposed of as they converted into common stock.
• On May 21, 2025, Allen was awarded a new grant of 8,759 Restricted Stock Units at a price of $0, under the company's 2023 Long-Term Incentive Plan.
• Following these transactions, Allen directly beneficially owns 19,387 shares of Common Stock and 8,759 Restricted Stock Units.
• Indirect beneficial ownership includes 22,757 shares held by the Allen Family Trust and 1,000 shares held by the Gammon Children's 2000 Trust, though Allen disclaims beneficial ownership of the latter.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates continued alignment of a director's interests with the company's long-term performance through equity grants and vesting. There are no negative transactions (e.g., large sales) reported.

Positives

• Director Dick Allen received a new grant of 8,759 Restricted Stock Units, indicating continued alignment of management incentives with shareholder interests.
• The vesting of 4,387 RSUs into common stock demonstrates the conversion of long-term incentives into direct equity ownership, reinforcing the director's stake in the company.

Future Outlook

The document does not provide specific forward-looking statements or guidance regarding the company's future performance, but the RSU grants imply a continued long-term incentive structure for directors.

Industry Context

This Form 4 filing reflects routine insider compensation and equity transactions for a director at a medical device company, specifically in the diabetes care sector. Such equity grants are common practice across industries to align director interests with long-term shareholder value.

Corporate Governance

Related Party Transactions

• The document notes indirect beneficial ownership through the Allen Family Trust dated October 12, 1981, which holds 22,757 shares.
• Indirect beneficial ownership also includes 1,000 shares held by the Gammon Children's 2000 Trust FBO Jake Allen Gammon, for which the reporting person is co-trustee but disclaims beneficial ownership.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with long-term shareholder value. The vesting of RSUs increases the director's direct equity stake in the company.
• Employees: While not directly impacting employees, the use of the 2023 Long-Term Incentive Plan for director compensation suggests a broader framework for equity incentives within the company.

Next Steps

• The newly awarded 8,759 Restricted Stock Units are expected to vest on the one-year anniversary of their grant date (May 21, 2025), subject to the terms of the 2023 Long-Term Incentive Plan.

Key Dates

Recommendation

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Grant, Director Compensation, Beneficial Ownership, Equity Incentive Plan